Relieve pain

Tertiary referral centres see the worst cases, so 42% is acetaminophen's share of the liver failures that reach those units and never a risk to anyone taking it. Doses in the accidental group were reconstructed from what patients recalled afterwards. The three routes overlap, so one person can sit in all of them and the percentages do not add to a hundred. The narcotic-combination finding is US-specific, since those products are not sold everywhere.

Single doses, in adults, for pain after an operation. That is the setting this drug performs best in, and it is not the setting most people take it in. Adverse-event reporting across the pooled trials was patchy, so the reassuring safety picture is thinner than the efficacy picture. The review dates from 2008 and has not been updated since.

Fourteen days in hospital with every meal provided is not ordinary home use, and 145 people is a small sample for a safety question. The 28-day study used 3 g rather than 4 g, so the two rates are not measuring the same exposure. Its placebo group had an 11% rate of its own, a reminder that this enzyme moves without any drug at all. The 4 g trial ran inside a hydrocodone product development programme, with several industry-affiliated authors.

A retracted trial leaves an absence of evidence, not evidence that the drug fails, and only the first of those is true here. Cochrane's inclusion rules were strict, which is why three trials survived a search of a much larger literature. This covers low back pain with no identified cause, not back pain traced to a known injury or disease.

No drug was tested against another here. These are numbers from separate trials in separate people, lined up side by side. The authors flag 13 of the drug and dose pairs as possibly affected by publication bias. All of it is a single dose for pain after an operation, which says nothing about taking either drug for weeks. And the arithmetic that makes the pair work is the same arithmetic that makes an unnoticed second acetaminophen product dangerous.

Short-term outcomes only, out to twelve weeks, so this says nothing about months of use. A group average does not rule out individuals who feel better on it. A separate network of 98 trials covering 69 medicines for the same condition rated confidence in every analgesic tested as low or very low, which is a different verdict from a confident null and worth holding alongside it. Four authors, lead and senior among them, had GlaxoSmithKline support for one of the pooled trials, a conflict that runs against the finding rather than towards it.

The nine-point line comes from a companion review by the same authors, not from this analysis, and other groups draw it elsewhere. The 192-trial network excluded any trial with fewer than 100 people per group and anything published outside English. Averages hide people, and some individuals in these trials did improve. Patients on paracetamol were also nearly four times as likely to show an abnormal liver function test, a laboratory result the authors say they cannot interpret clinically.

This is frequent episodic tension-type headache of moderate or severe intensity, not migraine, which the trials generally excluded, and not the chronic form. Ask an easier question and the number improves: for pain-free or only mild pain at two hours it is 10, and for avoiding a second painkiller it is 7.8. No trial was at low risk of bias on every count, though the reviewers put most of that down to thin reporting rather than bad conduct. The senior author declares grants and fees from analgesic manufacturers.

The trials ran one to six months and 64% concerned nerve pain, so this does not cover long-term use or the everyday aches cannabidiol is sold for. The cannabidiol-dominant result is a null across a whole product category, not a tested null for any particular product or dose.

Eighty-four separate comparisons across 23 conditions means some significant findings are expected by chance, and most were graded low or very low quality. The missing cannabidiol effect on pain is an absence of evidence inside these trials, not a tested null.

The community data are observational, so doctors steering higher-risk patients towards particular drugs cannot be ruled out. A relative risk says nothing about a given reader's own starting point. In the randomised trials the absolute excess came to about three extra major vascular events per 1,000 people treated for a year, one of them fatal. Those trial doses were high and sustained.

The people tested were mostly older adults with night-time leg cramps, not athletes cramping mid-race, so this settles the mineral rather than the sport. The pregnancy trials in the same review could not be pooled at all because their outcomes were reported inconsistently, and a separate Cochrane review graded those same trials as far less biased than this one did. Nothing here tests magnesium during exercise.

This is a strong recommendation resting on an absence of benefit rather than on demonstrated harm, and the guideline notes glucosamine's toxicity is low. It hardened from a conditional recommendation against glucosamine in 2012, so a reader may still meet the older advice. The search closed in 2018.

The 0.9 cm threshold is these authors' own choice rather than an agreed one, and a reader accepting a smaller threshold would read some of these intervals differently. Restricting by trial size excludes most of the older positive literature, so this is not the body of trials other reviews pool.

A placebo response of six in ten leaves very little room for a supplement to show a difference, and every arm could take up to 4,000 mg of paracetamol a day as rescue, narrowing the gaps further. The trial used glucosamine hydrochloride, not the sulfate salt sold in Europe as a medicine.

This is a continuation in the participants who met stricter X-ray criteria, not a fresh randomisation, so it carries the parent trial's high placebo response with it. Two years of dropout leaves less power, not more. The authors call the trends beneficial but not significant, which describes a null.

The result is fragile: its interval reaches to 0.002 mm, its p value is 0.046, and it survives only after adjustment for sex, weight and baseline severity. It is one of several comparisons, so a multiple-testing correction would likely remove it. Whether a tenth of a millimetre is felt is untested.

The subgroup was one of two specified in advance, but was never powered as a test of its own and no independent trial has repeated it. The Spanish trial is small, at 164 people, and its placebo group's larger improvement appears only when everyone randomised is counted, vanishing among completers.

All five datasets shared were independently funded, so the form distinction is tested only inside independent trials, and no dataset from the manufacturer whose product the argument is about was contributed. In the published record, form, sponsorship and concealment cannot be separated.

These were high, sustained, prescription-level doses in people with arthritis, not occasional tablets. Every regimen studied raised upper-gut complications, so this is a ranking inside a class that all carried the risk, not a safe option beside a risky one. Heart failure risk was roughly doubled by every drug in the analysis, naproxen included.

Median follow-up was 56 days, far too short to pick up the harms that build with long-term use, and the review says outright that it cannot make firm statements about safety. The reported adverse-event ratio of 1.04 almost certainly understates real-world harm for the same reason. Only English, German and Dutch language trials were eligible. No individual drug in the class outperformed another.

Diclofenac at 150 mg a day, the most effective oral option in the network, also carried a raised risk of people dropping out because of side effects, so the ranking rewards a preparation more people stopped taking. Only English-language trials with at least 100 patients per group were eligible, which leaves the smaller ones out. This covers knee and hip osteoarthritis, not pain in general. Several authors declare consulting relationships with industry.

The review rates most of its own evidence as low quality, chiefly because the trials reported their methods poorly, and the studies disagreed with each other substantially on the main pain comparison. Fifty-nine per cent of the trials were commercially funded and a further 31% did not say who paid. No one drug in the class could be shown safer or more effective than another, because most head-to-head comparisons rested on very few small trials.

Most of the included trials were at high risk of bias or raised concerns, and all of them ran for a year or less, so nothing here bears on years of combined use. The result for ulcer complications, as opposed to ulcers found by endoscopy, had an interval crossing no effect, from 0.10 to 1.07. Comparisons against other stomach medicines rest on single small studies. The trials were published between 1996 and 2014.

Most of the underlying data come from wisdom-tooth extraction in otherwise healthy adults, a standardised research model rather than everyday pain. These are single doses measured over four to six hours and say nothing about taking something repeatedly. The overview ran no statistical test between the drugs, so these numbers sit side by side and were never compared. Some drug and dose combinations were judged unreliable because of susceptibility to publication bias.

The best diclofenac figure rests on two studies, and some of the ketoprofen data come from 1980s trials with loosely defined outcomes. Around 5,900 participants' worth of registered but never fully reported efficacy data was identified and could not be obtained, which is the direction publication bias usually runs. Only 220 people across all 61 trials were given a tablet for comparison, so the comparison with swallowing one is thin.

About half the people using the carrier gel alone also counted as a success, roughly twice the usual response to a dummy pill, so part of what people feel comes from the vehicle and the act of rubbing rather than from the drug. Every trial in the topical review was in osteoarthritis, almost all of it knee osteoarthritis. Up to 6,000 participants' worth of completed but unpublished data was unavailable to the reviewers. Trials with fewer than 100 patients per group were excluded from the network.

This was an open treatment series with partly historical comparisons, because withholding an antidote to build a control group was not available. It dates from 1988 and the regimens have changed since, most notably to a shorter two-bag drip. The time bands rest on when people said they took the tablets, which is unreliable after an overdose and missing altogether when doses were spread across days. What survives all of that is the steepness of the gradient, which later guidelines reproduce.

One specialist transplant unit between 1992 and 2008, so these are the most severe cases and the mortality figures are not overdose mortality generally. Ingestion times and patterns were reconstructed from records after the fact. The repeat-dose group did die more often, 37.3% against 27.8%, but that gap did not hold up once age and alcohol misuse were accounted for, so it travels with those rather than clearly causing the worse outcome. Treatment of both patterns has changed since.

One urban public hospital clinic where 78% of parents had limited health literacy, so these are not general-population error rates. The benefit was concentrated in that group and was not detectable among parents with adequate literacy. It was a supervised measurement task rather than several days of dosing at home, and no child was harmed in it. The product tested was the older concentrated infant drops with a dropper, a format the United States has since changed.

Neither number marks a point where injury begins, and reading either as one is the most common mistake made with this drug. This is one product from one manufacturer in one country: other acetaminophen products, Tylenol's own included, print different strengths and different ceilings, and labels outside the United States differ again. The two figures also count differently, one per product and one across everything taken, which is exactly what makes them easy to swap.

None of these three figures is the dose at which injury begins, and the 10,000 mg line is set deliberately below where harm is expected so that clinicians act early. That threshold is also 200 mg per kilogram of body weight wherever that comes to less, so it is lower for a smaller person. It is Australian and New Zealand guidance, and the United Kingdom and United States set their own numbers. The 24,000 mg median describes people who had already reached liver failure, not a dose at which anyone should expect to.

Ten trials is a small base, and the review reports no pooled effect size at all. Soreness is self-reported. The dose ceiling is where the evidence stops, not where a harm begins, and the review is explicit that it cannot speak to anything above it.

The joint trial tested one branded product, and two of its authors work for the manufacturer and for the contract firm that ran it, so an independent repeat is still missing. Several outcomes in the largest synthesis, skin roughness among them, came out flat.

This is what one US label states, not a measurement of harm. Nothing here counts how often people do stack a second acetaminophen product on top, only that the label names it as the thing to avoid.

The two milligram figures are worked out from published molecular weights rather than quoted from a label, so they are close but should not be treated as an exact conversion factor. Both label versions were read on 6 September 2026, and printed strengths do change.

The label tells users not to drive while taking it and says nothing about the following morning, which is where the driving evidence sits. One product from one manufacturer in one country.

One real exception sits inside the largest of these studies: among American footballers alone, sweat measurements did carry a weak signal, and in the other ten sports none did. Beyond that, cramping was self-reported throughout, and serum electrolytes were sampled before and after a race rather than inside the muscle at the moment a cramp struck, which is where the theory actually locates the problem. Forty-three crampers is enough to rule out a dominant effect, not a small one.

Twenty crampers is a small group, and the finish-line enzyme gap is borderline at p = 0.034 with spreads wide enough to swallow it. The blood was drawn after the cramp, so muscle damage could as easily follow a cramp as cause one. Crampers and non-crampers only diverged in pace from 25 kilometres onward, which points back at effort. The paper's own abstract calls 20 of 88 a rate of 24 percent; it is 22.7 percent.

This is one manufacturer's label, so its choices are evidence about this product rather than about US labelling rules in general. The document also disagrees with itself: the index title says tablet where the Drug Facts panel and carton say capsule, and three different effective dates appear in it.

This is a reference monograph summarising labelling and formulary convention, not a study of what either ceiling does to anyone. The figures are United States labelling and differ by country. Monograph entries are revised continuously, so a later version may read differently.

The drip is given in a clinic under supervision, and nothing about that result transfers to a capsule taken at home. Some of the pooled studies assigned participants poorly, by the authors' own account. And each half of this rests on fewer than a thousand people.

These are relative risks, and the review does not supply an absolute one, which turns heavily on age and ulcer history. What counted as a serious complication varied between the pooled studies. The high-dose randomised data come from prescription-level regimens given to people with arthritis, not from the occasional tablet. Risk did not appear to keep climbing past the first month.

An online self-reported diary, so what people recorded may not be what they swallowed, and volunteers who sign up online are not a random sample. Going over the limit was worked out from the recorded times and doses, never checked against an independent record. The study counted behaviour and not harm, so it cannot say how many of those days caused anyone a problem. It ran in the United States, where pack sizes and single-pill doses differ from other markets.

Opioids showed a similar association, at 1.69, with no proposed bone-healing mechanism at all, which points at more painful or more severe fractures attracting stronger prescriptions rather than at the drugs themselves. Prescriptions filled stand in for drugs actually swallowed, and anything bought over the counter is invisible, which weakens the non-selective comparison specifically. Nonunion was rare, following 0.9% of episodes, so these odds sit on small absolute numbers.

These come from observational studies whose definitions of a serious complication and methods of recording who took what varied, which the authors flag themselves. The intervals are wide for the less-studied drugs, running from 1.07 to 17.81 for diflunisal. No absolute risk is supplied, and it turns heavily on age and ulcer history. Several of the drugs ranked are not in common use in most markets.

Not one of the pooled studies reported how often acute kidney injury happens without the drug, so there is no baseline here to turn these odds into a personal number, and the authors say so outright. Definitions of kidney injury differed between studies. The estimate for people with existing chronic kidney disease rests on five studies whose own figures ranged from 1.12 to 5.25. Prescription-based records miss anything bought over the counter.

The 10-percentage-point figure usually quoted from it is the one it rates low quality, with high bias risk and heavy disagreement. The benefit became uncertain whenever the analysis narrowed to trials that concealed allocation properly, to large trials, or to independently funded ones.

Chondroitin's knee-pain benefit is small, and whether it is worth having is unsettled. The largest trials put it below the smallest change a patient would notice, while Cochrane counts six people in a hundred helped.

Both reviews agree any benefit is small, and the Cochrane authors call the size probably not clinically relevant. Low confidence means the evidence cannot settle the question, not that the drugs were shown not to work. Only 7 of the 32 trials in the Cochrane review were judged at low risk of bias, almost half were industry-funded, and most were never registered. Neither review followed anyone long enough to speak to repeated use.

Two reviews of acute low back pain agree which way anti-inflammatories point; they disagree on whether trials this small, mostly unregistered and often industry-funded can say so.

Nearly seven in ten participants stopped taking the study drug and more than a quarter stopped follow-up altogether, which blunts every comparison the trial makes. It was funded by celecoxib's manufacturer. A non-inferiority design can show one drug is not clearly worse than another; it cannot show that any of them is safe. Everyone enrolled had arthritis and raised cardiovascular risk.

Whether celecoxib is as heart-safe as ibuprofen and naproxen is unsettled. Prescribing data rank it riskier; the one large trial found it no worse but dosed the drugs unequally, and no study has compared them at matched doses.

People were showing what they would do, not observed doing it at home, so this measures intent and understanding rather than behaviour. A public hospital clinic and a community practice were among the four sites, and the sample leans towards lower health literacy, which was itself one of two independent predictors of going over. The threshold scored against is the 4,000 mg liver warning rather than the lower per-product ceiling many labels now print, so against that figure the rates would be higher still.

Soreness is self-reported on a visual scale, and it is a symptom rather than a measure of recovery or performance. The abstract reports no publication-bias check, no risk-of-bias grading and no funding disclosure for the trials pooled, in a field where manufacturers fund much of the primary work.

How much BCAAs ease soreness is unsettled. The largest estimate rests on the thinnest base, never checked for publication bias, while three more careful syntheses of the same question land smaller.

Weak discrimination is not a screening test, and the authors do not offer it as one. Cramp history was self-reported, and sweat was collected during ordinary training, never during a cramp. Forearm patches estimate whole-body sweat sodium indirectly and carry real measurement error. One other significant result among roughly fourteen comparisons, potassium content in women, is what chance produces at that many tests.

The bar for counting as no worse was 40 points on a 0-to-500 pain scale, which is wide. The pair used glucosamine hydrochloride, the salt an earlier analysis concluded was ineffective, which makes matching a prescription drug harder to square with the rest of this literature rather than easier.

This review does not separate trials by manufacturer, by funder, or by how well allocation was concealed, the three things earlier analyses of this literature found decide the answer. Its combination conclusion rests on three trials. It reports direction and significance, no effect sizes.

Whether chondroitin and glucosamine ease pain turns on method, not data. Analyses splitting trials by funder, brand and trial quality find no difference a patient would notice; the review finding a benefit did not split them.

Eighty-nine runners, and the 18-point gap was not statistically significant, with an interval running from 4 points the other way to 41 points in favour. Kidney injury here means a creatinine rise measured at the finish line, a marker that often settles, not a clinical kidney outcome with follow-up. Runners who lost more weight during the race were independently more likely to be affected, so dehydration and the drug are tangled together in these numbers. Multi-day desert racing in heat is a deliberately stressed setting.

Four trials and 332 women leave enough room that a small real benefit could still be hiding inside the result. Cramps were defined and counted differently from trial to trial, which blunts any pooled figure. And this is cramps in pregnancy, not the ordinary night-time leg cramps most people mean.

The two trials used different magnesium compounds, so the split may be about which form sat in the capsule rather than about magnesium. Both groups improving by a third in the null trial points at expectation and the natural course of cramps doing much of the work. In the oldest positive trial, blood magnesium never actually rose, which makes it hard to credit magnesium with the improvement. And the trials counted cramps so differently that no single number can be drawn across them.

Both figures are relative, and neither set of authors supplies the baseline that would turn them into a personal number. The randomised trials used high, sustained, prescription-level doses in people with arthritis. The database analysis infers what people took from prescription records, so anything bought over the counter is invisible to it. A third pooled review of community databases put naproxen lowest of all, at 1.09.

Whether naproxen is the heart-safe painkiller is unsettled. Trials and prescribing databases disagree, and the databases disagree with each other, along study design rather than dose.